Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Each year in the United States, RSV is responsible for approximately 58,000 hospitalizations among children younger than 5 years old, with 100-500 pediatric…
On July 20, 2020, CureVac entered into a Collaboration and License Agreement with GlaxoSmithKline Biologicals SA covering the research, development and…
CureVac's CVnCoV COVID-19 vaccine produced just 47% efficacy against COVID-19 of any severity in the Phase 2b/3 HERALD study, well below the 70-95% efficacy…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
GSK and CureVac entered a strategic mRNA technology collaboration covering up to five mRNA-based vaccines and monoclonal antibodies for infectious diseases. GSK paid £104M (~$120M) upfront cash plus £30M (~$40M) reimbursable manufacturing reservation, with up to £294M (~$380M) in development/regulatory milestones plus tiered royalties. GSK also took a £130M (~$150M) equity stake.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / CureVac N.V. (this deal) | 2020 | $960M | — |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2020 deals · GlaxoSmithKline plc deals · Infectious Disease deals